SRPT Rentabilitas operasi Sarepta Therapeutics

SRPT (Sarepta Therapeutics) - tandha merek perusahaan

The operating margin on GURU.Markets demonstrates the real business efficiency of Sarepta Therapeutics, Inc. (SRPT), where -0.40 is the current value of the indicator. The stability of Sarepta Therapeutics, Inc. (SRPT) is based on its independence from macroeconomic factors, creating a defensive asset. High margins are ensured by a monopoly on unique gene therapy with patent protection, while the company's flexibility is maintained by outsourcing production and trials to external contractors.

SRPT: Rentabilitas dodolan operasi Sarepta Therapeutics 04.07.2022 - 20.11.2026

Rincian metrik keuangan lan pasar Sarepta Therapeutics, Inc. (SRPT)

- rega saham lan konsensus proyeksi valuasi:
Analisis wiwitan perusahaan:Sarepta Corp, SRPT
Produk merek Sarepta Corp

Investors require an objective tool to measure the efficiency of the issuer's resource management. This metric reflects the share of operating profit in revenue before financial expenses, allowing for an assessment of the business's fundamental stability through the monitoring of operating margin. Growth in this metric may be driven by one-time asset revaluations in 10-K filings. For Sarepta Therapeutics, Inc. (SRPT), this reflects the balance between gene therapy costs and compliance with strict ESG disposal standards. Effective energy saving in laboratories directly optimizes operating expenses.

Analisis perusahaan pesaing

Margin dodolan operasi TEM|QGEN - Tingkat bathi adhedhasar bathi operasi|Margin operasi IONS|RGEN - Rentabilitas dodolan operasi|Rentabilitas operasi Avidity RNA|Margin operasi CRISPR Therapeutics Corp CRSP|GeneDx Corp - Margin operasi|Ultragenyx Pharma (RARE) - Margin dodolan operasi|beamtx.com (BEAM) - Rentabilitas operasi|TWST: Rasio bathi operasi|TXG (10xgenomics.com) - Margin operasi|NTLA (Intellia Therapeutics, Inc.) - Rasio bathi operasi|Rentabilitas operasi Stoke Corp (STOK)|Rentabilitas kegiatan operasi BioLife|Margin operasi WVE (Wave Life Sciences Ltd)|MAZE: Rentabilitas dodolan miturut bathi operasi|Sionna Therapeutics, Inc. - Margin operasi|Tingkat bathi operasi PRME (Prime Medicine Inc)|TSHA (Taysha Gene Therapies, Inc.) - Margin dodolan operasi|QURE - Rentabilitas kegiatan operasi|MGTX (MeiraGTx Corp) - Margin operasi|Rentabilitas dodolan operasi REGENXBIO Inc. RGNX|Rentabilitas operasi Solid Biosciences (SLDB)|Ocugen Corp - Rentabilitas dodolan miturut bathi operasi|Rentabilitas operasi Pacific Biosciences PACB|Rasio bathi operasi BNTC (Benitec)|Design Corp - Margin operasi|Rocket Pharmaceuticals - Rasio bathi operasi|Rentabilitas dodolan miturut bathi operasi 4D Molecular Therapeutics, Inc.|Rentabilitas dodolan operasi Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Margin operasi|Rentabilitas dodolan operasi Editas EDIT|Margin operasi SLN|ProQR Therapeutics - Rentabilitas dodolan miturut bathi operasi|Margin operasi CDXS (Codexis, Inc.)|SGMO: Rentabilitas dodolan miturut bathi operasi|Nautilus Biotechnology - Margin operasi|Tingkat bathi operasi MGX (Metagenomi, Inc)|DTIL: Margin operasi|GBIO: Rasio bathi operasi|Rentabilitas operasi Boundless Bio Inc.|Margin dodolan operasi Exicure (XCUR)|Margin operasi IMNN|PHIO (Phio Pharmaceuticals Corp.) - Tingkat bathi operasi|Mustang Bio, Inc. - Margin dodolan operasi|RNAZ - Margin dodolan operasi|BNGO: Margin dodolan operasi|APDN (Applied DNA Sciences Inc) - Rentabilitas dodolan miturut bathi operasi|BLUE (Bluebird Bio) - Margin dodolan operasi|ImmunoPrecise Antibodies Ltd - Tingkat bathi operasi|OMGA (Omega Therapeutics Inc) - Margin operasi|Rentabilitas operasi OMIC|Rentabilitas operasi Regulus Therapeutics Inc. (RGLS)|Margin dodolan operasi Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Margin dodolan operasi|Tingkat bathi operasi TCON|UBX - Rentabilitas operasi